Abstract:Background: Despite the growing body of evidence on growth differentiation factor 15 (GDF-15) reference values for patients with existing cardiovascular disease, limited investigation has been dedicated to characterizing the distribution and prognostic impact of GDF-15 in predominantly healthy populations. Furthermore, current cutoff values for GDF-15 fail to account for the well-documented age-dependence of circulating GDF-15. Methods: From 810 community-dwelling older adults, we selected a group of apparently healthy participants (n = 268). From this sample, circulating GDF-15 was modeled using the generalized additive models for location scale and shape (GAMLSS) to develop age-dependent centile values. Unadjusted and adjusted Cox proportional hazards models were used to assess the association between the derived GDF-15 reference values (expressed as centiles) and all-cause mortality. Results: Smoothed centile curves showed increasing GDF-15 with age in the apparently healthy participants. An approximately three-fold difference was observed between the 95th and 5th GDF-15 centiles across ages. In a median 8.0 years of follow-up, 97 all-cause deaths were observed in 806 participants with eligible values. In unadjusted Cox regression analyses, the hazard ratio (95% CI) for all-cause mortality per 25-unit increase in GDF-15 centile was 1.80 (1.48-2.20) and dichotomized at the 95th centile, ≥95th versus <95th, was 3.04 (1.99-4.65). Age-dependent GDF-15 centiles remained a significant predictor of all-cause mortality in all subsequent adjusted models. Conclusions: Age-dependent GDF-15 centile values developed from a population of apparently healthy older adults are independently predictive of all-cause mortality. Therefore, GDF-15 reference values could be a useful tool for risk-stratification in a clinical setting. ClinicalTrials.gov Identifier: NCT01452178.

Humans without GDF15 reassure drug developers

Identification and characterization of human GDF15 knockouts

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

GDF15 is dispensable for the insulin-sensitizing effects of chronic exercise

Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15

GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

GDF15 deficiency promotes high fat diet-induced obesity in mice

Growth differentiation factor 15 protects against the aging‐mediated systemic inflammatory response in humans and mice

Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans

GDF15 is required for maintaining subcutaneous adipose tissue lipid metabolic signature

Supraphysiologic Administration of GDF11 Induces Cachexia in Part by Upregulating GDF15

Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role?

Growth differentiation factor 15 in a community-based sample: age-dependent reference limits and prognostic impact

GDF15 promotes weight loss by enhancing energy expenditure in muscle

GDF15 knockout does not substantially impact perinatal body weight or neonatal outcomes in mice

GDF11 induces mild hepatic fibrosis independent of metabolic health

Novel insights into the pleiotropic health effects of growth differentiation factor 11 gained from genome-wide association studies in population biobanks

Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial

Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise